JPWO2023204259A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2023204259A5 JPWO2023204259A5 JP2024505170A JP2024505170A JPWO2023204259A5 JP WO2023204259 A5 JPWO2023204259 A5 JP WO2023204259A5 JP 2024505170 A JP2024505170 A JP 2024505170A JP 2024505170 A JP2024505170 A JP 2024505170A JP WO2023204259 A5 JPWO2023204259 A5 JP WO2023204259A5
- Authority
- JP
- Japan
- Prior art keywords
- salt
- formula
- compound represented
- solvate
- medicament according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 37
- 150000003839 salts Chemical class 0.000 claims 36
- 239000012453 solvate Substances 0.000 claims 30
- 239000003814 drug Substances 0.000 claims 29
- 239000003795 chemical substances by application Substances 0.000 claims 26
- 230000008685 targeting Effects 0.000 claims 21
- 159000000000 sodium salts Chemical group 0.000 claims 8
- 229940124639 Selective inhibitor Drugs 0.000 claims 5
- 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 claims 5
- 101710116241 Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 claims 5
- 239000005557 antagonist Substances 0.000 claims 5
- 239000003112 inhibitor Substances 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 102200006538 rs121913530 Human genes 0.000 claims 5
- 239000002525 vasculotropin inhibitor Substances 0.000 claims 5
- RGCGBFIARQENML-JOCHJYFZSA-N (3R)-1'-[3-(3,4-dihydro-2H-1,5-naphthyridin-1-yl)-1H-pyrazolo[3,4-b]pyrazin-6-yl]spiro[3H-1-benzofuran-2,4'-piperidine]-3-amine Chemical compound N[C@@H]1c2ccccc2OC11CCN(CC1)c1cnc2c(n[nH]c2n1)N1CCCc2ncccc12 RGCGBFIARQENML-JOCHJYFZSA-N 0.000 claims 3
- UCJZOKGUEJUNIO-IINYFYTJSA-N (3S,4S)-8-[6-amino-5-(2-amino-3-chloropyridin-4-yl)sulfanylpyrazin-2-yl]-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine Chemical compound C[C@@H]1OCC2(CCN(CC2)C2=CN=C(SC3=C(Cl)C(N)=NC=C3)C(N)=N2)[C@@H]1N UCJZOKGUEJUNIO-IINYFYTJSA-N 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 229940126002 RMC-4630 Drugs 0.000 claims 3
- 229940125811 TNO155 Drugs 0.000 claims 3
- HISJAYUQVHMWTA-BLLLJJGKSA-N [6-(2-amino-3-chloropyridin-4-yl)sulfanyl-3-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl]methanol Chemical compound NC1=NC=CC(=C1Cl)SC1=C(N=C(C(=N1)CO)N1CCC2([C@@H]([C@@H](OC2)C)N)CC1)C HISJAYUQVHMWTA-BLLLJJGKSA-N 0.000 claims 3
- 229960000397 bevacizumab Drugs 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- NXQKSXLFSAEQCZ-SFHVURJKSA-N sotorasib Chemical compound FC1=CC2=C(N(C(N=C2N2[C@H](CN(CC2)C(C=C)=O)C)=O)C=2C(=NC=CC=2C)C(C)C)N=C1C1=C(C=CC=C1O)F NXQKSXLFSAEQCZ-SFHVURJKSA-N 0.000 claims 3
- 229940073531 sotorasib Drugs 0.000 claims 3
- PEMUGDMSUDYLHU-ZEQRLZLVSA-N 2-[(2S)-4-[7-(8-chloronaphthalen-1-yl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile Chemical group ClC=1C=CC=C2C=CC=C(C=12)N1CC=2N=C(N=C(C=2CC1)N1C[C@@H](N(CC1)C(C(=C)F)=O)CC#N)OC[C@H]1N(CCC1)C PEMUGDMSUDYLHU-ZEQRLZLVSA-N 0.000 claims 2
- 229940124988 adagrasib Drugs 0.000 claims 2
- 229960003852 atezolizumab Drugs 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- YGUFCDOEKKVKJK-UHFFFAOYSA-N 6-(4-amino-4-methylpiperidin-1-yl)-3-(2,3-dichlorophenyl)pyrazin-2-amine Chemical compound NC1(CCN(CC1)C1=CN=C(C(=N1)N)C1=C(C(=CC=C1)Cl)Cl)C YGUFCDOEKKVKJK-UHFFFAOYSA-N 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 229940125999 RMC-4550 Drugs 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- IKUYEYLZXGGCRD-ORAYPTAESA-N [3-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-6-(2,3-dichlorophenyl)-5-methylpyrazin-2-yl]methanol Chemical compound N[C@@H]1[C@@H](OCC11CCN(CC1)C=1C(=NC(=C(N=1)C)C1=C(C(=CC=C1)Cl)Cl)CO)C IKUYEYLZXGGCRD-ORAYPTAESA-N 0.000 claims 1
- IFVGQKHFUZRWNA-ZPZFBZIMSA-L [Na+].[Na+].Oc1c(cc(c2cccnc12)S([O-])(=O)=O)\N=N\c1ccc2cc(ccc2c1)S([O-])(=O)=O Chemical compound [Na+].[Na+].Oc1c(cc(c2cccnc12)S([O-])(=O)=O)\N=N\c1ccc2cc(ccc2c1)S([O-])(=O)=O IFVGQKHFUZRWNA-ZPZFBZIMSA-L 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 229940000425 combination drug Drugs 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022069320 | 2022-04-20 | ||
| JP2022069320 | 2022-04-20 | ||
| EP22207829.7 | 2022-11-16 | ||
| EP22207829 | 2022-11-16 | ||
| PCT/JP2023/015683 WO2023204259A1 (ja) | 2022-04-20 | 2023-04-19 | がんの治療又は予防用医薬 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2023204259A1 JPWO2023204259A1 (https=) | 2023-10-26 |
| JPWO2023204259A5 true JPWO2023204259A5 (https=) | 2024-04-01 |
| JP7565132B2 JP7565132B2 (ja) | 2024-10-10 |
Family
ID=88419939
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024505170A Active JP7565132B2 (ja) | 2022-04-20 | 2023-04-19 | がんの治療又は予防用医薬 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20250262194A1 (https=) |
| EP (1) | EP4512401A4 (https=) |
| JP (1) | JP7565132B2 (https=) |
| CN (1) | CN119031911A (https=) |
| TW (1) | TW202404586A (https=) |
| WO (1) | WO2023204259A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025146040A1 (zh) * | 2024-01-01 | 2025-07-10 | 华健未来(成都)科技股份有限公司 | 芳香酰肼类衍生物及其医药用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20230523T1 (hr) | 2013-09-06 | 2023-08-04 | Taiho Pharmaceutical Co., Ltd. | Antitumorski agens i sredstvo za poboljšavanje antitumorskog efekta |
| JP7377679B2 (ja) * | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法 |
| JP2021063014A (ja) | 2019-10-10 | 2021-04-22 | 国立大学法人 東京大学 | 白血病治療薬 |
| WO2021076655A1 (en) * | 2019-10-15 | 2021-04-22 | Amgen Inc. | Combination therapy of kras inhibitor and shp2 inhibitor for treatment of cancers |
| AR121078A1 (es) * | 2020-01-22 | 2022-04-13 | Chugai Pharmaceutical Co Ltd | Derivados de arilamida con actividad antitumoral |
| CN115279376A (zh) * | 2020-01-31 | 2022-11-01 | 维瑞斯特姆股份有限公司 | 用于治疗异常细胞生长的组合疗法 |
| WO2022018875A1 (ja) * | 2020-07-22 | 2022-01-27 | 中外製薬株式会社 | アリールアミド誘導体を含む細胞増殖性疾患の治療又は予防用医薬組成物 |
| CN115803024B (zh) * | 2020-07-22 | 2025-01-10 | 中外制药株式会社 | 包含芳基酰胺衍生物的组合物 |
| BR112023025916A2 (pt) * | 2021-06-09 | 2024-02-27 | Chugai Pharmaceutical Co Ltd | Combinação de um inibidor de braf e um inibidor de mek, uso de uma combinação, método para o tratamento ou profilaxia de câncer, composições farmacêuticas e invenção |
-
2023
- 2023-04-19 US US18/857,507 patent/US20250262194A1/en active Pending
- 2023-04-19 EP EP23791907.1A patent/EP4512401A4/en active Pending
- 2023-04-19 CN CN202380034317.4A patent/CN119031911A/zh active Pending
- 2023-04-19 WO PCT/JP2023/015683 patent/WO2023204259A1/ja not_active Ceased
- 2023-04-19 JP JP2024505170A patent/JP7565132B2/ja active Active
- 2023-04-20 TW TW112114697A patent/TW202404586A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020515578A5 (https=) | ||
| ES2252519T3 (es) | Acido valproico para el tratamiento de cancer de mama, cancer de colon, cancer de cabeza y cuello, carcinoma de celulas pequeñas de pulmon y leucemia, en combinacion con radioterapia. | |
| US20210161837A1 (en) | Methods for treating cancer with rorgamma inhibitors | |
| JP6557744B2 (ja) | 抗腫瘍剤及び抗腫瘍効果増強剤 | |
| JP2020510662A5 (https=) | ||
| JP2024075668A (ja) | 抗体-薬物コンジュゲートとチューブリン阻害剤の組み合わせ | |
| Hassan et al. | New life for immunotoxin cancer therapy | |
| JP2018504418A5 (https=) | ||
| JPWO2021085653A5 (https=) | ||
| US20130274281A1 (en) | Methods of treating metastatic breast cancer with 4-iodo-3-nitrobenzamide and irinotecan | |
| JP2009501800A5 (https=) | ||
| JP2017031160A5 (https=) | ||
| JP2021502423A5 (https=) | ||
| US20180222983A1 (en) | Methods, compositions, and kits for treatment of cancer | |
| TW202537643A (zh) | 抗體-藥物結合物之用途 | |
| JP2024513505A (ja) | 腫瘍を治療するための組成物及び方法 | |
| JP2021503915A5 (https=) | ||
| JPWO2023204259A5 (https=) | ||
| Couto et al. | Biologic activity of the novel small molecule STAT3 inhibitor LLL12 against canine osteosarcoma cell lines | |
| JPWO2021260579A5 (https=) | ||
| JP2018524361A5 (https=) | ||
| JP2022169780A5 (https=) | ||
| JP7750884B2 (ja) | HIF-2α阻害剤とレンバチニブの組み合わせを使用して、癌またはフォンヒッペル・リンダウ病を処置するための方法 | |
| JP2015518053A5 (https=) | ||
| TW201300105A (zh) | 治療頭頸鱗狀細胞癌之相乘藥物組合物 |